New Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions

These four collaborative talks from UCSF and John Muir Health specialists shine a light on recent study results that should inform treatment planning for patients with a variety of GI, breast, lung and blood cancers. Here's guidance on care for locally advanced rectal cancer, including strategies for reducing harm (such as from pelvic radiation); results from studies of CDK4/6 inhibitors in HR+ breast cancer and ways to reduce side effects without losing benefits; an explanation of how effective use of pembrolizumab or osimertinib can optimize care in early-stage lung cancer; and the scoop on three newly approved bispecific antibodies for lymphomas – who they’re for, how they’re given, the data on efficacy and safety – as well as immune therapies for multiple myeloma.